Is discontinuation of hormone replacement therapy possible for patients with late-onset hypogonadism?

International Journal of Urology

Volumn 15, Issue 7, 2008, Pages 625-629

  Tsujimura, Akira ^a   Takada, Shingo ^a   Matsuoka, Yasuhiro ^a   Hirai, Toshiaki ^a   Takao, Tetsuya ^a   Miyagawa, Yasushi ^a   Nonomura, Norio ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Discontinuation; Hormone replacement therapy; Late onset hypogonadism; Symptom; Testosterone

Indexed keywords

CHORIONIC GONADOTROPIN; TESTOSTERONE; TESTOSTERONE ESTER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LABORATORY TEST; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RATING SCALE; SELF RATING DEPRESSION SCALE; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; CHORIONIC GONADOTROPIN; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 47249160704     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02061.x     Document Type: Article

References (33)

1. Nieschlag E, Swerdloff R, Behre HM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur. Urol. 2005 48 : 1 4.
2. Comhaire FH. Andropause: hormone replacement therapy in the ageing male. Eur. Urol. 2000 38 : 655 62.
3. Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J. Urol. 1997 157 : 849 54.
4. Morley JE. Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin. Proc. 2000 75 (Suppl S83 7.
5. Morley JE, Perry HM 3rd. Androgen treatment of male hypogonadism in older males. J. Steroid Biochem. Mol Biol. 2003 85 : 367 73.
6. Tsujimura A, Matsumiya K, Takao T et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male 2005 8 : 175 9.
7. Morley JE. Androgens and aging. Maturitas 2001 38 : 61 71 discussion 3.
8. Morales A, Buvat J, Gooren LJ et al. Endocrine aspects of sexual dysfunction in men. J. Sex. Med. 2004 1 : 69 81.
9. Morley JE, Perry HM 3rd. Androgen deficiency in aging men. Med. Clin. North Am. 1999 83 : 1279 89, vii.
10. Vermeulen A. Andropause. Maturitas 2000 34 : 5 15.
11. Morales A, Heaton JP, Carson CC 3rd. Andropause: a misnomer for a true clinical entity. J. Urol. 2000 163 : 705 12.
12. Tsujimura A, Matsumiya K, Matsuoka Y et al. Bioavailable testosterone with age and erectile dysfunction. J. Urol. 2003 170 : 2345 7.
13. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 1996 156 : 1173 7.
14. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 2004 89 : 503 10.
15. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A Biol. Sci. Med. Sci. 2003 58 : 618 25.
16. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. 2003 88 : 2673 81.
17. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J. Clin. Psychopharmacol. 1999 19 : 19 27.
18. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry 2000 57 : 141 7 discussion 55 6.
19. Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J. Clin. Psychiatry, 2001 62 : 406 12.
20. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch. Intern. Med. 2006 166 : 1660 5.
21. Nair KS, Rizza RA, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl. J. Med. 2006 355 : 1647 59.
22. Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J. Androl. 2007 28 : 875 82.
23. T'Sjoen G, Feyen E, De Kuyper P, Comhaire F, Kaufman JM. Self-referred patients in an aging male clinic: much more than androgen deficiency alone. Aging Male 2003 6 : 157 65.
24. T'Sjoen G, Goemaere S, De Meyere M, Kaufman JM. Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004 29 : 201 14.
25. Tsujimura A, Matsumiya K, Miyagawa Y et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int. J. Impot. Res. 2005 17 : 259 63.
26. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002 5 : 74 86.
27. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 2006 91 : 4335 43.
28. Yoshida NM, Kumano H, Kuboki T. Does the Aging Males' Symptoms scale assess major depressive disorder? A pilot study. Maturitas 2006 53 : 171 5.
29. Sato Y, Tanda H, Kato S et al. Prevalence of major depressive disorder in self-referred patients in a late onset hypogonadism clinic. Int. J. Impot. Res. 2007 19 : 407 10.
30. Tenover JS. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 1992 75 : 1092 8.
31. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J. Urol. 1981 126 : 372 5.
32. Johnson DE, Haynie TP. Phosphorus-32 for intractable pain in carcinoma of prostate. Analysis of androgen priming, parathormone rebound, and combination therapy. Urology 1977 9 : 137 9.
33. Marks LS, Mazer NA, Mostaghel E et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006 296 : 2351 61.